Mindray(SZ:300760)2023-04-27 16:00Financial Performance - The company's revenue for Q1 2023 reached ¥8,364,281,841, representing a 20.47% increase compared to ¥6,943,108,994 in the same period last year[3]. - Net profit attributable to shareholders was ¥2,571,117,273, up 22.14% from ¥2,105,071,901 year-over-year[3]. - Basic earnings per share rose to ¥2.1260, reflecting a 22.36% increase from ¥1.7375 in the previous year[3]. - Total operating revenue for Q1 2023 reached ¥8,364,281,841, a 20.4% increase from ¥6,943,108,994 in the same period last year[17]. - Net profit for Q1 2023 was ¥2,572,339,003, representing a 22.1% increase compared to ¥2,106,972,682 in Q1 2022[18]. - Operating profit for the current period was ¥2,899,684,588, up from ¥2,401,535,649, marking a 20.8% increase year-over-year[18]. - Total comprehensive income for Q1 2023 was ¥2,577,475,440, up from ¥2,025,451,984, reflecting a growth of 27.3%[19]. - Total operating costs for the current period were ¥5,572,679,803, which is a 20.4% increase from ¥4,630,030,820 in the same period last year[17]. Cash Flow and Assets - The net cash flow from operating activities increased by 53.30%, amounting to ¥1,333,357,505, primarily due to higher cash receipts from sales of goods and services[6]. - Cash flow from operating activities amounted to ¥1,333,357,505, compared to ¥869,750,366 in the same quarter last year, indicating a 53.3% increase[20]. - The company's cash and cash equivalents amounted to CNY 23.91 billion, up from CNY 23.19 billion, indicating a growth of about 3.1%[14]. - The total assets at the end of the reporting period were ¥48,558,714,507, a 3.88% increase from ¥46,745,236,809 at the end of the previous year[3]. - The total liabilities decreased to CNY 13.89 billion from CNY 14.75 billion, a reduction of about 5.8%[16]. - The equity attributable to shareholders rose to CNY 34.65 billion from CNY 31.98 billion, showing an increase of approximately 8.3%[16]. Research and Development - R&D investment in Q1 2023 was CNY 938 million, accounting for 11.21% of operating revenue, with a year-on-year increase of 26.30%[11]. - Research and development expenses increased to ¥852,300,844, a rise of 21.1% from ¥703,945,494 in the previous year[17]. - As of March 31, 2023, the company had applied for a total of 8,892 patents, including 6,357 invention patents, with 4,187 patents granted[11]. - The company launched new products in Q1 2023, including the AF-600 fully automated microbial identification and susceptibility analysis instrument and the HyLED C series surgical lights[11]. Market and Strategic Initiatives - The company plans to enhance product competitiveness and market penetration by focusing on high-end hospitals and large third-party laboratory chains[10]. - The domestic ICU market saw a significant increase in demand for critical care equipment, leading to a shift in production capacity towards these products[10]. - The company expects a rebound in the performance of in vitro diagnostics and medical imaging businesses, as well as overseas markets in the upcoming months[10]. - The establishment of the Zhuhai-Macao Remote Ultrasound Alliance aims to improve medical services in the Greater Bay Area and Guizhou Province[12]. - The company is committed to enhancing basic medical infrastructure and talent training to provide better healthcare services to a wider population[12]. Shareholder Information - The company reported a total of 63,099 common shareholders at the end of the reporting period[7]. - Smartco Development Limited and Magnifice (HK) Limited were the top two shareholders, holding 26.98% and 24.49% of shares, respectively[7]. Social Responsibility - The company donated medical equipment worth USD 200,000 to Turkey for earthquake relief efforts, demonstrating its commitment to social responsibility[13]. - In Q1 2023, Mindray's AED devices successfully treated 20 patients in China, contributing to a total of 168 lives saved since inception[13]. - The company plans to complete the new campus of Dazhang Middle School by June 2025, which will significantly enhance the educational capacity[13]. Other Financial Information - The company received government subsidies amounting to ¥61,723,021 during the reporting period[5]. - Other income for the current period was ¥199,644,189, an increase from ¥113,998,291 in the same period last year[17]. - Cash outflow from investment activities totaled $535,236,403, an increase from $381,172,038 in the previous period, resulting in a net cash flow from investment activities of -$497,127,763 compared to -$294,278,032[21]. - Cash outflow from financing activities was $37,237,728, significantly lower than $1,023,069,387 in the previous period, leading to a net cash flow from financing activities of -$37,237,728 compared to -$1,023,069,387[21]. - The impact of exchange rate changes on cash and cash equivalents was -$69,123,212, compared to -$15,757,666 in the previous period[21]. - The net increase in cash and cash equivalents was $729,868,802, a turnaround from a decrease of -$463,354,719 in the previous period[21]. - The beginning balance of cash and cash equivalents was $18,973,643,833, up from $15,132,728,506 in the previous period[21]. - The ending balance of cash and cash equivalents reached $19,703,512,635, compared to $14,669,373,787 in the previous period[21]. - The company’s first quarter report for 2023 was not audited[22].